Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.19.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Consolidated Statements Of Operations    
Revenues, net $ 376,656 $ 657,271
Operating expenses:    
Cost of implants and other costs 170,953 323,608
Research and development 151,768 450,722
Selling, general and administrative 4,422,600 2,739,967
Impairment of acquired license 250,000
Depreciation and amortization 7,353 33,888
Total operating expenses 5,002,674 3,548,185
Loss from operations (4,626,018) (2,890,914)
Other income (expenses):    
Interest expense, net (1,959,207) (11,148,525)
Gain on settlement of debt 847 296,592
Gain (loss) on change in fair value of derivative liability (15,962,822)
Total other income (expenses) (1,958,360) (26,814,755)
Net loss before provision for income taxes (6,584,378) (29,705,669)
Income taxes
Net Loss (6,584,378) (29,705,669)
Non-controlling interest 72,487
NET LOSS ATTRIBUTIBLE TO BIOCORRX, INC. $ (6,511,891) $ (29,705,669)
Net loss per common share, basic and diluted $ (2.60) $ (12.77)
Weighted average number of common shares outstanding, basic and diluted 2,506,229 2,326,786